Spleen natural killer cell activity in mice implanted with allogeneic fibroblast-like tumour cells following in vivo exposure to beta-interferon, interleukin-1 or indomethacin.
By using CBA/J mice as responders and a murine fibroblast-like cell line spontaneously transformed in vitro (Swiss-12) as the material to be implanted, the development of tumours and the natural killer (NK) cell activity levels in the spleen were tested, respectively, in relation to the in vivo administration of several immunomodulators; i.e., beta-interferon (beta-IF), macrophage-derived interleukin-1 (IL-1), or indomethacin (IND), as a prostaglandin inhibitor. For each immunomodulating agent, two separate schemes of administration were used as follows: for 14 days, on alternate days, preceding the tumour cell implantation, or for 14 days, on alternate days, after tumour cell implantation. In both schemes, beta-IF was able to reduce the tumour size as well as to stimulate the NK cell cytotoxicity. On the other hand, only pre-treatment with IL-1 and only post-treatment with IND exhibited such an effect.
D000818:Animals; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D007213:Indomethacin / Q000494:pharmacology*; D007370:Interferon Type I / Q000494:pharmacology*; D007375:Interleukin-1 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D013154:Spleen / Q000276:immunology*; D013997:Time Factors
D007370:Interferon Type I; D007375:Interleukin-1; D007213:Indomethacin